Evercore ISI Issues Positive Forecast for Cardinal Health (NYSE:CAH) Stock Price

Cardinal Health (NYSE:CAH) had its price objective increased by Evercore ISI from $250.00 to $260.00 in a report released on Friday,MarketScreener reports. Evercore ISI’s target price points to a potential upside of 14.61% from the company’s current price.

Other equities research analysts also recently issued reports about the company. UBS Group set a $260.00 price target on Cardinal Health and gave the company a “buy” rating in a research note on Friday. Leerink Partners boosted their target price on shares of Cardinal Health from $240.00 to $268.00 and gave the company an “outperform” rating in a research report on Thursday. Mizuho increased their price target on shares of Cardinal Health from $222.00 to $235.00 and gave the stock an “outperform” rating in a research report on Friday. Barclays assumed coverage on shares of Cardinal Health in a research note on Monday, December 8th. They set an “overweight” rating and a $243.00 price target on the stock. Finally, Wall Street Zen upgraded Cardinal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Fifteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $241.27.

Cardinal Health Trading Down 0.1%

Shares of CAH opened at $226.85 on Friday. The firm has a fifty day simple moving average of $206.92 and a two-hundred day simple moving average of $179.97. The firm has a market cap of $53.90 billion, a PE ratio of 32.64, a P/E/G ratio of 1.51 and a beta of 0.64. Cardinal Health has a 1-year low of $120.72 and a 1-year high of $230.81.

Cardinal Health (NYSE:CAH) last released its quarterly earnings results on Thursday, February 5th. The company reported $2.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.31 by $0.32. The firm had revenue of $65.63 billion for the quarter, compared to the consensus estimate of $64.88 billion. Cardinal Health had a negative return on equity of 92.50% and a net margin of 0.68%.The company’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same period last year, the business posted $1.93 EPS. As a group, research analysts forecast that Cardinal Health will post 7.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Cardinal Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Evoke Wealth LLC purchased a new position in shares of Cardinal Health during the 4th quarter worth $327,000. Ignite Planners LLC increased its stake in Cardinal Health by 17.0% during the fourth quarter. Ignite Planners LLC now owns 2,125 shares of the company’s stock worth $457,000 after acquiring an additional 309 shares during the last quarter. Axxcess Wealth Management LLC raised its stake in shares of Cardinal Health by 217.1% in the fourth quarter. Axxcess Wealth Management LLC now owns 38,500 shares of the company’s stock valued at $7,912,000 after acquiring an additional 26,359 shares in the last quarter. Kingdom Financial Group LLC. acquired a new stake in Cardinal Health in the fourth quarter valued at approximately $72,000. Finally, Global Retirement Partners LLC raised its stake in Cardinal Health by 73.3% in the fourth quarter. Global Retirement Partners LLC now owns 6,169 shares of the company’s stock valued at $1,268,000 after buying an additional 2,609 shares in the last quarter. Institutional investors and hedge funds own 87.17% of the company’s stock.

Cardinal Health News Summary

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Q2 results and raised outlook — Cardinal reported Q2 FY2026 revenue up ~19% to $65.6B and non‑GAAP EPS of $2.63 (beat), and raised fiscal‑year non‑GAAP EPS guidance to $10.15–$10.35; management cited strong specialty medicine demand and improved segment performance. PR Newswire
• Positive Sentiment: Analyst upgrade and price‑target lift — Leerink Partners raised its price target from $240 to $268 and kept an outperform rating, signaling more upside from current levels. MarketScreener
• Positive Sentiment: Street commentary and momentum coverage — Multiple outlets (Barron’s, Reuters, Zacks, TipRanks, 24/7 Wall St.) highlight the beat, raised guidance and accelerating specialty drug volumes, which has driven momentum interest in the stock. Examples: Reuters coverage on the outlook and Barron’s note on guidance lifts. Reuters
• Neutral Sentiment: Earnings call & transcripts available — Management commentary and slides from the Q2 call confirm the drivers behind the beat (specialty medicine, margin expansion, buybacks); these provide detail but no new surprises beyond the release. MSN Transcript
• Neutral Sentiment: Momentum stock analysis — Zacks highlights style‑score based momentum attributes, which can attract technical and quant funds but also increase volatility. Zacks
• Negative Sentiment: Valuation and historical ROE signal — After the rally the stock trades at an elevated P/E (~34x) and company data show a negative trailing return on equity metric, which could concern value‑focused investors and limit upside absent continued execution. Background valuation metrics

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.